Stereotactic radiotherapy for early breast cancer in elderly women

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of Stereotactic Body Radiation Therapy (SBRT) as a non-invasive treatment option for elderly women aged 75 and older with early-stage breast cancer who are not candidates for surgery. The study aims to provide an effective local treatment alternative for patients who typically receive only hormonal therapy due to age-related comorbidities. By focusing high-intensity radiation on the tumor, the trial seeks to control the primary tumor without the need for surgical intervention. The eligibility criteria include women with specific tumor characteristics and a confirmed diagnosis of local disease only.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 75 years
* Histologically confirmed diagnosis of local disease only (cT1-T2 N0 M0)
* Luminal like A or B (estrogen receptor positive and/or progesterone receptor positive and Her2 negative Tumors)
* SBRT within 2 months after hormonal therapy start

Exclusion Criteria:

* Metastatic Disease
* Evidence of loco-regional nodal disease
* Multifocal or multicentric tumors
* Prior radiotherapy to the region of the study cancer that would result in overlap of therapy fields
* Concurrent systemic disorders that contraindicate radiotherapy

Where it's running

• Fondazione Policlinico Tor Vergata
  Rome, Rome, Italy Recruiting

Study contacts

• Principal investigator: Rolando Maria D'Angelillo — Fondazione Policlinico Tor Vergata
• Study coordinator: Laura Cedrone
• Email: radioterapia@ptvonline.it
• Phone: +393669879224

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pre-Treatment Breast DCE-MRI AI Model to Predict Benefit from Neoadjuvant Chemo in Locally Advanced Triple-Negative Breast Cancer

  This study tests an AI model using pre-treatment breast MRI to see if it can identify which locally advanced triple-negative breast cancer patients will benefit most from neoadjuvant chemotherapy.

  Recruiting Fujian Cancer Hospital · Fuzhou, Fujian and 4 other locations · NCT07880600

• Using Doppler ultrasound resistive index to distinguish benign and malignant breast masses

  This study will test whether comparing Doppler resistive index values from a breast mass and nearby healthy breast tissue can help tell if a solid breast lump in women is benign or malignant.

  Recruiting Karamanoğlu Mehmetbey University · Karaman, Lütfen Seçiniz. · NCT07465523

• Time‑restricted eating (8‑hour window) during chemotherapy for breast cancer: feasibility and acceptability

  This trial will test whether eating all daily food within an 8‑hour window is practical and acceptable for people starting chemotherapy for stage I–III breast cancer (and some stage IV with oncologist approval).

  Recruiting at 2 sites University of Illinois Chicago · Chicago, Illinois and 1 other locations · NCT07387445

• FYI on MRI: decision support to help high-risk Black and Latina women decide about screening breast MRI

  This project will test whether adding a decision aid to risk assessment and nurse referral helps high-risk Black and Latina women make informed choices about screening breast MRI.

  Recruiting Georgetown University · Washington D.C., District of Columbia · NCT06892275

• Treatment for locally advanced HER2-positive breast cancer using a combination of drugs

  This study is testing a new combination of drugs to see if it can help women with locally advanced HER2-positive breast cancer get better before surgery.

  Recruiting First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT06234137

• Comparing two types of breast radiation therapy after surgery

  This study is testing whether partial breast radiation or whole breast radiation works better for women with small, node-negative breast cancer after surgery.

  Recruiting at 30 sites Phase 3 Ontario Clinical Oncology Group (OCOG) · Darlinghurst, New South Wales and 30 other locations · NCT05417516

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.